Finanzas de Rapport Therapeutics Inc (RAPP)RAPPRapport Therapeutics Inc

Evaluating the bottom line, Rapport Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -425.11%, while the net margin is -382.36%. These profitability ratios, combined with a Return on Equity (ROE) of -39.96%, provide a clear picture of how effectively RAPP converts its operational activities into shareholder value.

In the context of the broader market, RAPP competes directly with industry leaders such as VSTM and TSHA. With a market capitalization of $1.27B, it holds a significant position in the sector. When comparing efficiency, RAPP's gross margin of 100.00% stands against VSTM's 89.92% and TSHA's N/A. Such benchmarking helps identify whether Rapport Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company reported zero revenue for several quarters, with a significant net loss of $56.6 million in Q2 2026. The gross margin is 100% for Q1 2026, but this is not sustainable without revenue generation. The current ratio is high at 15.72, indicating good short-term liquidity, but the overall financial outlook remains concerning due to ongoing losses.